Uterine corpus choriocarcinoma
disease diseaseOn this page
Also known as body of uterus choriocarcinoma (disease)body of uterus gestational choriocarcinomachoriocarcinomagestational choriocarcinoma of body of uterusgestational uterine corpus choriocarcinomauterine corpus gestational choriocarcinoma
Summary
Uterine corpus choriocarcinoma (MONDO:0004491) is a disease and 11 clinical trials. Top therapeutic interventions include dactinomycin, methotrexate, and etoposide phosphate. A subtype of malignant germ cell tumor of corpus uteri — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 11
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | uterine corpus choriocarcinoma |
| Mondo ID | MONDO:0004491 |
| DOID | DOID:8187, DOID:8188 |
| NCIT | C27246 |
| UMLS | C1336904 |
| MedGen | 234466 |
| GARD | 0024033 |
| Anatomy (UBERON) | UBERON:0009853 |
| Is cancer (heuristic) | no |
Also known as: body of uterus choriocarcinoma (disease) · body of uterus gestational choriocarcinoma · choriocarcinoma · gestational choriocarcinoma of body of uterus · gestational uterine corpus choriocarcinoma · uterine corpus gestational choriocarcinoma
Disease family
Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine corpus cancer › malignant germ cell tumor of corpus uteri › uterine corpus choriocarcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 11.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 4 |
| Not specified | 4 |
| PHASE3 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02375204 | PHASE3 | ACTIVE_NOT_RECRUITING | Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors |
| NCT00003702 | PHASE3 | COMPLETED | Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia |
| NCT01535053 | PHASE3 | COMPLETED | Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia |
| NCT04684368 | PHASE2 | RECRUITING | A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT |
| NCT00190918 | PHASE2 | COMPLETED | A Trial for Patients With Gestational Trophoblastic Disease |
| NCT02396511 | PHASE2 | COMPLETED | TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma |
| NCT02664961 | PHASE2 | TERMINATED | Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) |
| NCT04562558 | Not specified | ACTIVE_NOT_RECRUITING | Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia |
| NCT05564026 | Not specified | RECRUITING | Molecular Epidemiology of Pediatric Germ Cell Tumors |
| NCT00294177 | Not specified | UNKNOWN | Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma |
| NCT01267851 | Not specified | UNKNOWN | Clinical Database and Biobank of Patients With Gynecologic Neoplasms |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DACTINOMYCIN | 4 | 3 |
| METHOTREXATE | 4 | 3 |
| ETOPOSIDE PHOSPHATE | 4 | 1 |
| IFOSFAMIDE | 4 | 1 |
| CAROTUXIMAB | 3 | 2 |
| CHEMBL4748391 | 0 | 3 |